Pfizer’s AI-Powered Feasibility and Cost Efficiency: The Future of Clinical Trial Recruitment
At the 2025 SCOPE Europe conference, industry leaders examined how artificial intelligence (AI) is reshaping feasibility assessment and patient...
Search results for:
pfizer
Pfizer Talzenna & Xtandi Improve Survival in mCRPC
Pfizer announced positive Phase 3 TALAPRO-2 trial results for TALZENNA (talazoparib) combined with XTANDI (enzalutamide) in treating metastatic castration-resistant...
Pain Treatment Market 2024-2029: Medtronic, Abbott, GSK, Pfizer, J&J
The global conventional and alternative pain treatment market, valued at $96.2 billion in 2024, is projected to reach $144.2...
Pfizer & Atavistik Bio Partner to Discover Allosteric Therapeutics
Atavistik Bio and Pfizer have partnered to discover novel allosteric therapeutics for two undisclosed targets chosen by Pfizer. Atavistik...
Pfizer Appoints New Chief Scientific Officer
Pfizer has appointed Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development,...
FDA Approves Pfizer’s Abrysvo RSV Vaccine for Adults
Pfizer recently received approval from the U.S. Food and Drug Administration (FDA) for ABRYSVO®, its respiratory syncytial virus (RSV)...
Pfizer Recalls Worldwide Supplies of Sickle Cell Disease Treatment
Pfizer has voluntarily withdrawn OXBRYTA (voxelotor) from all markets due to an imbalance in vaso-occlusive crises and fatal events...
FDA Approves Pfizer BioNTech COVID KP.2 Omicron Vaccine: A Health Milestone
The U.S. Food and Drug Administration (FDA) has approved Pfizer and BioNTech’s Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine for...
Pfizer and BioNTech Announce Results From New Combo Vaccine for Influenza and COVID-19
Pfizer and BioNTech have released preliminary findings from a Phase 3 clinical trial evaluating their mRNA vaccine candidate that...
Pfizer Announces Remarkable Results of Abrysvo® for RSV in Immunocompromised Adults: A Transformative Breakthrough
Pfizer has reported positive results from a clinical trial evaluating its vaccine, ABRYSVO, in immunocompromised adults at risk of...